Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:3/3/2015)... 3, 2015 Based on its recent ... & Sullivan recognizes Neopeutics, Inc. with the 2015 ... Leadership. Neopeutics has demonstrated a remarkable ability to ... easily adaptable set of drug discovery instruments. It ... failing compounds in the early stages of the ...
(Date:3/3/2015)... YORK , March 3, 2015  PlasmaTech Biopharmaceuticals, ... advancing protein biologic therapies and oncology supportive care products, ... Annual ROTH Capital Partners Conference which is being ... Niguel in Dana Point, California.  PlasmaTech,s ... to present a corporate update on Wednesday, March 11, ...
(Date:3/3/2015)... 3, 2015  Tru-D SmartUVC will exhibit the ... Perioperative Registered Nurses, Surgical Conference and Expo 2015 ... Patient Safety Awareness Week March 7 through 11. ... clinical practice and professional development. ... http://photos.prnewswire.com/prnh/20150302/178998LOGO   Tru-D SmartUVC,s ...
Breaking Medicine Technology:Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 2Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 3Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 4Frost & Sullivan Applauds Neopeutics' Commitment to Accelerating the Delivery of New Nature-Based Pharmaceuticals and Therapeutics 5PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference 2Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 2Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 3
(Date:3/3/2015)... (PRWEB) March 04, 2015 The report ... on the therapeutic development for Alopecia. Alopecia is the ... the two main types of alopecia. Causes for alopecia ... Symptoms of alopecia may include male pattern hair loss, ... hair. Alopecia can be classified as focal or diffuse ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The first ... the National Sleep Foundation. The event brings recognition to ... over. , According to the Centers for ... problems of one form or another. Too little or ... risk of physical illness and depression, and even a ...
(Date:3/3/2015)... 2015 The combinatorial, multi-gene GeneSight ... treatment outcomes for patients with depression, and their ... the individual genes that comprise the test, according ... Mayo Clinic and Assurex Health, and published online ... proprietary technology of the GeneSight Psychotropic test is ...
(Date:3/3/2015)... 2015 The North America ... grow from $1,224.6 million to $1,694.6 million, ... and 2019. , Browse through the TOC ... for an analysis of industry trends and ... and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , An ...
(Date:3/3/2015)... BOCA RATON, Fla - (March 3, 2015) (PRWEB) March ... First Class Vacations, Inc. (FCV), an innovator in the ... next step in his trailblazing expansion plan. To fulfill ... forward with the addition of 400 fun, exciting and ... Raton, Florida headquarters and a news sales center planned ...
Breaking Medicine News(10 mins):Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 2Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 3
... Through a new advertising campaign being launched in Memphis today, ... and prevention. Cervical cancer is caused by high-risk types ... the only FDA-approved HPV test, has selected Memphis as a ... ad for the digene HPV Test on local ...
... Family, Encourage Charitable Giving , BOSTON, Feb. 9 ... today launched the ,Light a Candle, program -- offering consumers ... their loved ones. Visitors can now light candles or ... million current and historical obituaries available on the popular national ...
... Ga. and ATLANTA, Feb. 9 Greenway ... electronic health records,(EHR), practice management and interoperability ... clearinghouse, today announced a,partnership designed to improve ... physician practices. Through this agreement, both companies ...
... Television Week for providing "vital information" to viewers, ... program that tells the compelling and inspirational stories of real ... Denver, CO; Albany, NY; Austin, TX; Salt Lake City, UT; ... the program now airs on nearly 260 television stations across ...
... MINNEAPOLIS, Feb. 9 ARKRAY USA, Inc., the 5th ... clearance from,the U.S. Food and Drug Administration for the ... This new system requires no coding, displays results ... size, and was developed to use the same,affordable test ...
... to learn about Heart Failure-how to prevent it and to ... Week February 8-14, 2009 Heart Failure Society of ... Available at www.abouthf.org NEW YORK, ... for February 8-14. This is a time for ...
Cached Medicine News:Health News:New Local TV Ad Campaign To Educate Memphis Women About Cervical Cancer Prevention and HPV Testing 2Health News:New Local TV Ad Campaign To Educate Memphis Women About Cervical Cancer Prevention and HPV Testing 3Health News:New Local TV Ad Campaign To Educate Memphis Women About Cervical Cancer Prevention and HPV Testing 4Health News:Tributes.com Launches 'Light a Candle' Program In Support of the American Heart Association and Heart Health Month 2Health News:Tributes.com Launches 'Light a Candle' Program In Support of the American Heart Association and Heart Health Month 3Health News:Greenway Medical Technologies and Navicure Form Partnership to Streamline Claims Management Process 2Health News:Greenway Medical Technologies and Navicure Form Partnership to Streamline Claims Management Process 3Health News:Greenway Medical Technologies and Navicure Form Partnership to Streamline Claims Management Process 4Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 2Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 3Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 4Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 5Health News:'Sharing Miracles' Television Program Expands Network to Key U.S. Markets 6Health News:ARKRAY USA Receives FDA Clearance on GLUCOCARD(R) 01-mini Blood Glucose Monitoring System 2Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 2Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 3
The STALIF stand-alone anterior lumbar fusion cage is the latest product development from Surgicraft. STALIF is the natural evolution of the Hartshill Horseshoe, which has over 10 years clinical suc...
... Computerized Vision Tester offers the latest ... the many features of our complete ... delegating the refraction, electronic data collection, ... an incredible interest in this product! ...
Orbital Retractor, schepens Retractors, overall length:154mm....
... capability extending to 80, the M700 provides ... field, allowing peripheral defects that are not ... explored. Practice Management Integration provides the logical ... Medmont Studio package the practitioner is now ...
Medicine Products: